Two Phase II Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma Following Progression on VEGF-Targeted Therapy

Background The clinical activity of allosteric mTOR inhibitors in renal cell carcinoma (RCC) may be limited by upstream activation of PI3-Kinase/Akt resulting from mTORC1 inhibition. Based on this rationale, two independent Phase II trials (Perifosine 228 and 231) were conducted to assess the efficacy and safety of the novel Akt inhibitor perifosine in patients with advanced RCC who had failed prior VEGF-targeted therapy.